Le Lézard
Classified in: Ebola virus, Science and technology, Business
Subject: ACC

Annual General Meeting of AB SKF


GOTHENBURG, Sweden, March 26, 2024 /PRNewswire/ -- The Annual General Meeting of Aktiebolaget SKF was held on Tuesday, 26 March 2024.

The income statements and the balance sheets were adopted, together with the Board's proposal for distribution of dividend. A dividend of SEK 7.50 per share was approved. To be entitled to receive the dividend, shareholders must be recorded in the share register on Thursday, 28 March 2024.

The Board members and the CEO were discharged from liability for their administration of the company for the financial year 2023.

Hans Strĺberg, Hock Goh, Geert Follens, Hĺkan Buskhe, Susanna Schneeberger, Rickard Gustafson, Beth Ferreira, Therese Friberg, Richard Nilsson and Niko Pakalén were re-elected as Board members.

Hans Strĺberg was elected Chair of the Board. Hĺkan Buskhe was elected Vice Chair of the Board by the Board of Directors at the Statutory Board meeting.

The Meeting resolved that remuneration to Board members shall be paid in accordance with the following:

1.  SEK 2,750,000 to the Chair of the Board, SEK 1,375,000 to the Vice Chair of the Board and SEK 900,000 to each of the other Board members; and

2.  SEK?350,000 to the Chair of the Audit Committee, SEK 250,000 to each of the other members of the Audit Committee, SEK 200,000 to the Chair of the Remuneration Committee, SEK 150,000 to each of the other members of the Remuneration Committee, SEK 200,000 to the Chair of the Sustainability and Ethics Committee, SEK 150,000 to each of the other members of the Sustainability and Ethics Committee.

A prerequisite for obtaining remuneration is that the Board member is elected by the General Meeting and is not employed by the company.

The Meeting approved the Board's remuneration report and the Board's proposal for a resolution on SKF's Performance Share Programme 2024. The programme is proposed to cover senior managers and key employees in the SKF Group with an opportunity to be allotted, free of charge, SKF B shares. Under the programme, not more than in total 1,000,000 SKF B shares may be allotted. The allotment of shares shall be related to the level of achievement of the Total Value Added (TVA) target, as defined by the Board, and the SKF Group's CDP Climate Change score performance measure during the three-year programme period. The programme does not entail any dilution of the company's shares. The principal terms and guidelines of the programme can be found in the Board's proposal at www.skf.com.

Aktiebolaget SKF       (publ) 

CONTACT:

For further information, please contact:
PRESS: Carl Bjernstam, Head of Media Relations
tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail: [email protected]

INVESTOR RELATIONS: Sophie Arnius, Head of Investor Relations
tel: 46 31-337 8072; mobile: 46 705-908 072; [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/annual-general-meeting-of-ab-skf,c3951822

The following files are available for download:

https://mb.cision.com/Main/637/3951822/2697970.pdf

20240326 Annual General Meeting of AB SKF

https://news.cision.com/skf/i/gotahom-4jpg-png-highpreview-1278,c3282832

Götahom 4jpg png highpreview 1278

SOURCE SKF


These press releases may also interest you

at 08:05
BigCommerce , an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands and retailers, today announced the company has hired veteran ecommerce and technology industry leader Travis Hess as its president. Hess...

at 08:05
Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego. The Respiratory Innovation Summit (RIS) has been established by the...

at 08:05
Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced that it is expanding its early access program for its complex DNA synthesis services. More customers around the world will now be able to take advantage of the...

at 08:05
Boundless Bio , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief...

at 08:05
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study...

at 08:05
Phonak, a leading global provider of life-changing hearing solutions, today announces an FDA cleared self-replacement option for Phonak Lyric, the world's only 100% invisible hearing aid? that provides 24/7 hassle-free hearing? with proven tinnitus...



News published on and distributed by: